The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

The state and behaviour of a cell can be influenced by both genetic and environmental
factors. In particular, tumour progression is determined by underlying genetic aberrations …

A high tumour mutational burden (hypermutation) is observed in some gliomas,,,–; however,
the mechanisms by which hypermutation develops and whether it predicts the response to …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and
biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through …